



## Final Appraisal Recommendation

Advice No: 0816 – March 2016

### Prucalopride (Resolor<sup>®</sup>) 1 mg and 2 mg film-coated tablets

Limited submission by Shire Pharmaceuticals Ltd

#### Recommendation of AWMSG

Prucalopride (Resolor<sup>®</sup>) is recommended as an option for use within NHS Wales for the treatment of chronic constipation in men in whom laxatives fail to provide adequate relief.

#### Additional note(s):

- Please refer to the recommended NICE Technology Appraisal 211 for prucalopride use in women.
- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 918), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Shire Pharmaceutical Contracts Ltd
Date of first issue	March 2016
Last reviewed	May 2019

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0816: prucalopride (Resolor<sup>®</sup>) 1 mg and 2 mg film-coated tablets. March 2016.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>